Clinical Trial

A Study to Assess CLBR001+ABBV-461 in Subjects With Locally Advanced or Metastatic Breast Cancer

Terminated Phase 1
View on ClinicalTrials.gov →
Why the trial stopped
Business Decision
Summary
The goal of this clinical trial is to evaluate CLBR001 and ABBV-461 as a treatment for patients with locally advanced or metastatic breast cancer. The goals are to establish the safety and efficacy of the combination therapy while establishing the optimal biologic doses. Patients will be administered a single infusion of CLBR001 cells followed by cycles of ABBV-461 with regular assessments of safety and disease response to treatment.
Protocol Amendment History 8 changes
critical Trial terminated 2026-05-29
critical Reason stopped changed: — → Business Decision 2026-05-29
notable Enrollment reduced: 20 -> 10 participants 2026-05-29
notable Primary completion moved earlier: 2026-06 -> 2026-04-09 2026-05-29
minor Completion moved earlier: 2026-06 -> 2026-04-09 2026-05-29
critical Trial status changed: Recruiting → Active, Not Recruiting 2026-04-04
notable Primary completion moved earlier: 2028-11 -> 2026-06 2026-04-04
minor Completion moved earlier: 2028-11 -> 2026-06 2026-04-04
Trial Details
NCT Number NCT06878248
Lead Sponsor Calibr, a division of Scripps Research
Conditions Breast Cancer Metastatic, Locally Advanced Breast Cancer (LABC), Malignant Neoplasm of Breast, Triple Negative Breast Cancer (TNBC), Hormone Receptor-Positive Breast Cancer, HER2 + Breast Cancer
Enrollment 10 participants
Start Date 2025-04-17
Primary Completion 2026-04-09 (estimated)
Study Completion 2026-04-09 (estimated)
Updated on ClinicalTrials.gov 2026-05-28